Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?